Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 12, 2019 16:05 ET | Source: Optinose, Inc.

Optinose Announces $150 Million Debt Financing from Pharmakon

YARDLEY, Pa., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported...
August 12, 2019 16:02 ET | Source: Optinose, Inc.

Optinose Reports Second Quarter 2019 Financial Results and Recent Operational Highlights

XHANCE net revenue grew 68% to $6.7 million from first to second quarter 2019 XHANCE prescriptions increased 51% from first to second quarter 2019 Company expects XHANCE net revenues for 2019 to be...
August 01, 2019 16:30 ET | Source: Optinose, Inc.

Optinose to Report Second Quarter 2019 Financial Results and Corporate Updates on August 12, 2019

YARDLEY, Pa., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
June 20, 2019 08:00 ET | Source: Optinose, Inc.

Optinose to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference

YARDLEY, Pa., June 20, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
June 19, 2019 16:30 ET | Source: Optinose, Inc.

Optinose Named a 2019 Best Place to Work by Philadelphia Business Journal

YARDLEY, Pa., June 19, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
May 09, 2019 07:00 ET | Source: Optinose, Inc.

Optinose Reports First Quarter 2019 Financial Results and Recent Operational Highlights

Company reports first quarter 2019 total revenues of $4.5 million. XHANCE first quarter net product revenues grew to $4.0 million XHANCE prescriptions increased 59% from fourth quarter 2018 to first...
April 25, 2019 07:00 ET | Source: Optinose, Inc.

Optinose to Report First Quarter 2019 Financial Results and Corporate Updates on May 9, 2019

YARDLEY, Pa., April 25, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
March 06, 2019 07:00 ET | Source: Optinose, Inc.

Optinose Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Operational Highlights

Company reports fourth quarter and full year 2018 net XHANCE revenue of $3.0 million and $7.1 million XHANCE prescriptions increased 50 percent from Q3 to Q4 of 2018 Conference call and webcast to...
February 27, 2019 07:00 ET | Source: Optinose, Inc.

Optinose to Report Fourth Quarter 2018 Financial Results and Corporate Updates on March 6, 2019

YARDLEY, Pa., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
February 19, 2019 07:00 ET | Source: Optinose, Inc.

Optinose Announces Issuance of Four Additional U.S. Patents Covering XHANCE

YARDLEY, Pa., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...